Frontlight ResearchEarly access
Metastatic breast cancer trials in Germany
52 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
- Where
- Ansbach, Augsburg, Bayreuth, Berlin, Bottrop, Braunschweig, Bremen, Chemnitz, Cologne, Dresden, Duesseldorf, Essen, Frankfurt am Main, Frankfurt Am Main, Fürstenwalde, Goslar, Hanover, Heidelberg, Homburg, Kassel, Leipzig, Mainz, Mayen, Munich, Ravensburg, Rostock, Saarbruecken, Stralsund, Stuttgart, Suhl, Tuebingen, Weinheim, Wiesbaden, Winnenden, Witten, Worms, Wuppertal
- Age
- 18 years and over
- People
- 176
- Run by
- GBG Forschungs GmbH
See details and how to joinNCT06201234 · EU 2023-504925-38-00 - Phase 4Active, not recruitingCombination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
- Where
- Aalen, Amberg, Augsburg, Berlin, Biberach, Bonn, Braunschweig, Bremen, Cologne, Donauwörth, Dresden, Duesseldorf, Erlangen, Eschweiler, Frankfurt, Freiburg im Breisgau, Hamburg, Hildesheim, Hösbach, Karlsruhe, Kassel, Kempten (Allgau), Krefeld, Limburg, Moenchengladbach, Munich, Neuss, Nuremberg, Paderborn, Potsdam, Rheine, Schwaebisch Hall, Stralsund, Tuebingen, Ulm, Wiesbaden
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Prof. Wolfgang Janni
See details and how to joinNCT05362760 · EU 2024-511209-49-00